SpineguardALSGD
▼ ネガティブ資本関連度
SpineGuard reported a wider H1 2026 net loss of 1,226 K€ as revenue fell 32% amid US asset sale costs and deferred proceeds
銘柄への影響 3
Aging Population
Biotech & Genomic Medicine
テーマインパクト
カバレッジ外企業 1
Omnia Medical非上場± 混在
資本関連度
Omnia Medical is named only as the buyer of SpineGuard's US subsidiary assets, with no impact on Omnia itself described